Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Solid tumors that have failed auto transplant or are ineligible to receive auto transplant~* Relapsed AML in 1st relapse or 2nd or 3rd CR~* Relapsed ALL if they fail to attain an initial remission or if they relapse within 1 year following the discontinuation of chemotherapy.~* Greater than or equal to 6 months and \<26 years old~* Suitable haploidentical donor available~Exclusion Criteria:~* Leukemia with \>25% blasts in bone marrow at the time of admission to the HSCT unit.~* Serum bilirubin \>3 mg/dl~* GFR \<40 ml/min/1.73 mw~* Cardiac left ventricular ejection fraction \<40%~* HIV+~* Pregnant

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): patients will undergo a standard pre-transplant evaluation, but will also have blood drawn to evaluate their HLA class I killer immunoglobulin-like receptor (KIR) ligand typing. Parents will undergo KIR genotyping and phenotyping, and a donor will be selected based on which parent shows the greatest degree of KIR receptor-ligand mismatching. Once the donor has been selected he/she will undergo a peripheral blood stem cell (PBSC) collection utilizing G-CSF and GM-CSF for stem cell mobilization. The PBSC collection will be performed utilizing standard procedures. The PBSC will then be processed in the UW BMT Laboratory in order to deplete the graft of T cells. This will be accomplished using the CliniMACS cell separation system. T cell depletion is a standard procedure for patients receiving haploidentical stem cell grafts. The resulting stem cell product will be analyzed for T cell, stem cell and NK cell content.

Based on this trial design, predict the completion outcome and termination type (if applicable).